Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel

Journal of Clinical Oncology

Volumn 19, Issue 9, 2001, Pages 2493-2503

  Hidalgo, M ^a   Aylesworth, C ^a   Hammond, L A ^a   Britten, C D ^a   Weiss, G ^a   Stephenson J , Jr ^a   Schwartz, G ^a   Patnaik, A ^a   Smith, L ^a   Molpus, K ^a   Felton, S ^a   Gupta, E ^a   Ferrante, K J ^a   Tortora, A ^a   Sonnichsen, D S ^a   Skillings, J ^a   Rowinsky, E K ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 METHYLTHIOMETHYLPACLITAXEL; BMS 184476; PACLITAXEL; PACLITAXEL DERIVATIVE; UNCLASSIFIED DRUG;

ADVANCED CANCER; ARTHRALGIA; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG SOLUBILITY; FEBRILE NEUTROPENIA; HUMAN; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MYALGIA; NEUROTOXICITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0035340984     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.9.2493     Document Type: Article

References (26)

1. Paclitaxel
2. Clinical toxicities encountered with paclitaxel (Taxol)
3. Preclinical antitumor activity of a new paclitaxel analog BMS-184476
4. Hypersensitive reactions from Taxol
5. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL
6. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans
7. Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors
8. Docetaxel
9. One-hour infusion paclitaxel infusions: Review of safety and efficacy
10. Clinical phase I study with one-hour paclitaxel infusion
11. Carcinoma of unknown primary site: Treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide
12. Sequences of Taxol and cisplatin: A phase I and pharmacologic study
13. Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: Rapid development of neurotoxicity is dose-limiting
14. Hypersensitivity reactions to teniposide (VM-26): An analysis
15. Histamine release in dogs by Cremophor EL and its derivatives: Oxethylated oleic acid is the most effective constituent
16. Complement activation by Cremophor EL as a possible contributor to paclitaxel: An in vitro study
17. Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions
18. Anaphylactoid reactions associated with parenteral cyclosporine use: Possible role of Cremophor EL
19. Evaluation of the linearity of docetaxel pharmacokinetics
20. Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo
21. Normal viability and altered pharmacokinetics in mice lacking mdr 1-type (drug transporting) P-glycoproteins
22. Effect of the paclitaxel vehicle. Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice
23. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer
24. Paclitaxel as a radiosensitiser: A proposed schedule of administration based on in vitro data and pharmacokinetic calculations
25. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: Clinical pharmacokinetic implications
26. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients